Clinical Trials | October 27, 2021
Dr Lal PathLabs to acquire Suburban Diagnostics for Rs 925 crore
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
Filing marks first protein-based vaccine submitted to MHRA for authorization
A total of 12 generic medicines have been included in the list
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
This unique record was made possible by collating hard copies of the books in a structured manner
Subscribe To Our Newsletter & Stay Updated
